Comments

You must log in or register to comment.

Dishankdayal t1_izweb29 wrote

Billions of doses within the year. Astonishing feat.

6

Fit-Signature8414 t1_izwebm2 wrote

I can’t believe how much money they make from sales in the USA. How is this possible?

6

DJCPhyr t1_izwfgsd wrote

I didn't need convincing that we need to regulate drug prices, but you just convinced me again anyways.

46

Ghostforever7 t1_izwooek wrote

Why use millions as unit of measurement, if you are doing thousands of millions? It's called a billion.

3

[deleted] t1_izwvndd wrote

I once compared the prices of medication I regularly use, in the US and in my country. Still can't stop thinking of how bizarre the difference is. For some drugs I would have to pay up to 100 times more in the US. And it's the same brand name, not a generic drug. Like what kind of added value can medication acquire to justify this unthinkable price difference.

How can such healthcare system even exist lol. It's like the whole population of the USA are constantly exploited by the insurance companies which thrive on the unjustifiably overpriced cost of medical services and drugs.

12

HindsightIs4040 t1_izwxzn0 wrote

See how little they actually spend on R&D! And how much they spend on marketing!

51

Jacuul t1_izxn2tx wrote

That's just a made-up strawman. You can criticise people even if they are black/transgender/etc, noone is preventing that, look at how Herschel Walker lost in Georgia despite being black, perhaps had something to do with being a terrible candidate regardless of skin colour.

3

PullinUpBootstraps t1_izxokns wrote

Only thing I would change are the values and go with billions and one decimal place instead of millions and three.

1

HumphreyLee t1_izxu3lv wrote

Yes, NOW they can get away with extortionate prices on drugs, because of “woke” culture or some weird bullshit going on in your head. They haven’t been doing this for decades or anything the old fashioned way of “millions in lobbying dollars to make politicians look the other way and not write pricing legislation.” Holy shit, the length people like you go to feel aggrieved. Let’s throw out literal decades of neocapitalist history you can actually track through donation dollars and written law and make up some nonsense about a minority getting a job as “the real cause.” What fragile little worlds you all live in.

1

avengerintraining t1_izybxoq wrote

It’s not R&D (which is usually very small scale), but once a drug is developed the process to get it onto market is pretty significant. I’m not sure what how these buckets are divided exactly and depending on the product, scale up, clinical trials, regulatory testing and validation processes have A LOT of administrative and other costs. So like 1 dollar spent on R&D requires 10 dollars spent elsewhere to complete the process.

18

wolf1moon t1_izyei3u wrote

It's expensive but it's still no where near a major cost and almost certainly bucketed into r&d. Otherwise you'd see it there. Besides, they buy up smaller companies that have already done it so they don't have to.

5

wolf1moon t1_izyen20 wrote

The tax rate is so aggravating

1

skicolorado t1_izyget9 wrote

As a healthcare provider, you wouldn’t believe how much these companies spend in marketing. Routinely buy lunch for offices with ~50 employees, fancy provider dinners, targeted ads, etc..

3

Xdsin t1_izygjjg wrote

This assumes that the R&D is successful.

What would this look like if their mRNA vaccine failed or more competitors beat them to the punch?

You also have them responding to a Pandemic. Which would make their returns on investment higher.

6

Xdsin t1_izygtv7 wrote

One of the benefits of a single payer system like Canada or UK is that you are one buying entity that has more bargaining power over drug companies. You can regulate drug prices.

3

Aussieh t1_izyh8h3 wrote

what's the name of this type of chart?

1

trelos6 t1_izyjzbr wrote

Which one is employees salaries?

1

miniTotent t1_izym3oy wrote

If it’s part of bringing a product to market and it isn’t broken out on its own then it should be lumped into R&D. Scaling up and getting regulatory approvals is the development part of research and development.

2

Jftwest t1_izyuluj wrote

38% is pretty high profit margin, no doubt, but I think other companies are comparable? Just off the top of my head, I think Apple (retail) is over 40%.

1

qa2fwzell t1_izyy181 wrote

Hey make sure you get your 50th COVID booster

0

0tt0attack t1_izyy8dm wrote

You know that the tax laws are bull shit when the effective tax rate of $8.65 billion is 4%.

20

STA_Alexfree t1_izyyr5q wrote

I work for Pfizer’s oncology R&D group and they’re pretty good at only spending money to develop the most promising drugs and killing off projects early that won’t likely produce a viable drug (like 90% of projects)

5

STA_Alexfree t1_izz6eow wrote

Can be anytime really and there’s lots of “go/no-go” checks along the way but the vast majority get killed off before human clinical trials. That is one of the largest costs for drug R&D

3

[deleted] t1_izz7im7 wrote

Yeah, I remember seeing stat a few years back that for every drug that makes it to market, close to 19 are cancelled before that point. Partially why completed drugs are priced so high before the patent runs out

1

[deleted] t1_izz8g9t wrote

It doesn’t change the amount of tax they pay, it just lowers their effective tax rate. The $356 million in income tax reported here isn’t the same thing as the tax they actually pay the IRS

When stock options are exercised by employees, this lowers their income tax expense without lowering profit, which results in a lower tax rate

It’s a weird adjustment because it’s basically just theoretical, but most large companies have large adjustments for it each year

2

[deleted] t1_izz9ow8 wrote

>are you suggesting they pay more than this to the IRS

Could be more, could be less. And there’s no way to see it, it’s not public info. Usually when companies report very low rates though, their actual tax paid tends to be higher

I’m not saying that it’s good for society, I just think most people are under the impression it’s due to some shady accounting or loopholes. But it’s basically just normal stuff

2

[deleted] t1_izzcpmv wrote

This is just for income tax though, and hardly any citizens pay 30%

In actuality though, Pfizer is paying much more than 4% in corporate tax. They pay 21% on US earnings and probably a similar average rate on their foreign ops

2

VorianFromDune t1_izzg4fl wrote

I just would like to highlight how much they are making in USA versus Developed Europe. Both being the same kind of economy, with the same population.

Looking at their gross profit, it is almost like 75% of their profit come from the USA. It makes me wonder, aren’t their vaccines a little bit overpriced in the USA compared to the rest of the whole world ?

1

DevinCauley-Towns t1_izzh6yq wrote

I don’t think people believe the accounting practices are shady per se. It’s more so that the system is broke if a company can generate 10s of billions in revenue AND profit while only paying a few % (1.5% of revenue in this case) in taxes. I don’t care what legal or illegal means are used to get there. They simply should be paying a much more substantial amount of their profits towards the government and therefore society at large. Especially in a case where some these companies are causing tremendous harm like many pharmaceutical companies today.

1

Ghostforever7 t1_izzj0xz wrote

I guess I learned something new. That being said Short scale is total trash and a much more confusing and complicated way of displaying numbers. The point is this is an English graphic and short scale is the official scale of English speaking countries.

1

innocentlookingstew t1_izzr08n wrote

Anyone has a good idea or explanation why provision for tax is only 4%? I would assume the business to get taxed higher. Or is it included in one of the categories already, and if so, what are these 4% provisions?

2

[deleted] t1_izzw13t wrote

It’s hard to tell since their quarterly filings don’t provide reconciliations, but combining that info with their 2021 total filing, here’s my best explanation as a CPA:

  1. Pfizer sells into a lot of foreign countries with different tax rates than the US. On their 2021 tax rec, this was the single largest driver of their low tax rate

  2. They’ve received a lot of tax credits from their vaccine distribution both in 2021 and 2022

  3. They had IRS resolutions in 2022 that reduced their tax expense in prior years, which reduces this years income tax expense

  4. The actual tax they paid was much higher than the $356 million reported here. It’s just that income tax expense includes deferred taxes for future years, which are very negative right now. For reference, they’ve paid almost $5 billion of tax for 2022 so far

1

Sea_no_evil t1_j00067r wrote

This is why the US is so against nationalized health care. The profits are too big.

0

wolf1moon t1_j00i7dx wrote

Where are you getting that percentage? Compare like to like. They're paying 4% if that data is real, as their effective tax rate. For citizens, the effective tax rate is 14.6%, see source below.

The top 50% of taxpayers paid 97.1% of all federal income taxes in 2018. Among those taxpayers, the average income tax rate was 14.6% and the average tax paid was $20,663. The OECD reported that the U.S. "tax wedge" for the average single worker was 28.4% in 2021.

https://www.thebalancemoney.com/what-the-average-american-pays-in-taxes-4768594

1

[deleted] t1_j00ik50 wrote

If you look at their 10-Q, a lot of their in-process R&D this year came from acquisitions, which are capitalized on the balance sheet and them amortized over 15 years

Also, any foreign R&D they have abides by foreign reporting rules, in which development costs are also capitalized

1

[deleted] t1_j00ipeg wrote

>Where are you getting that percentage

It’s the US corporate tax rate. The 4% figure is based on their reported profits, but this isn’t the same as taxable income

The actual tax paid so far in 2022 for them is around $5 billion. It’s just that their effective tax rate includes deferred taxes in future years, which are very negative

1

kirlandwater t1_j00jqs6 wrote

That’s great and all, but that $8.6b in net profit is my biggest concern. Drug makers blame high R&D costs to develop new meds on exorbitant drug costs, but it’s all just going right back to shareholders, whether directly through dividends, retained earnings, or share buybacks.

And that $8.6b in net profit is just the last 3 months. These figures are just Q3 2022. FY2021 they brought in a whopping $21.98b in net profit from $81.3b in revenue. And spending $13.8b in R&D. 59% more in net profit attributed to shareholders than R&D.

source: page 51

1

wolf1moon t1_j00n4ix wrote

That makes sense they would capitalize it, but the amortization is still a tiny percentage. There's no way to slice this that isn't very little money spent on r&d compared to the profits. I used to work health care supply chain and r&d was never a major expense. The selling costs including buying employees boats to take doctors out on "as friends" because it didn't count as bribery if you didn't give the doctor the boat directly. Crazy shit

1

QuizardNr7 t1_j00ormx wrote

Side effect I would say. In a completely free market the price of life saving insulin is just very high. And regulation seems to prevent effective cost competition. Newly developed drugs might see less investment if the US market weren't so juicy, I would give you that.

1

kirlandwater t1_j00p1jn wrote

> in a completely free market the price of life saving insulin is just very high

But that’s not entirely true. Yes it’s needed to live, but so is water. And water isn’t exorbitantly expensive. Insulin is VERY cheap to make and because lawmakers aren’t willing to combat evergreen-ing patents, competition simply all but isn’t allowed. If they’d allow generics to come to market, the price would plummet.

In a completely free market we’d have a race to the bottom.

1

[deleted] t1_j01irx4 wrote

They do spend quite a bit on R&D normally though. It’s just that a large portion of R&D in 2022 comes from acquisitions, so it’s reported on the balance sheet instead of the income statement

1

kirlandwater t1_j02k894 wrote

Acquisitions definitely aren’t R&D. They’ll expand they’re product line, yes, but those products already existed or were researched and developed without Pfizer’s M&A.

One could argue acquisitions allow for more efficient R&D as synergies between newly acquired research teams eliminate redundancies, but you’d need to look into what research PFE was doing prior to the acquisition and if they’re buying something they already were working on, and additionally you’d walk into an even stronger case against consolidating the drug makers into an oligopoly, which isn’t good for consumers.

1

[deleted] t1_j03ak30 wrote

It’s not the acquisition itself, it’s the in-process R&D that transfers to Pfizer. It’s not allowed to be expensed, it has to be capitalized. They money they spend on the acquisition for R&D replaces money they would’ve otherwise spent on internal R&D

1

kirlandwater t1_j03b13u wrote

Right, but that in-process R&D is just that, in process. PFE doesn’t deserve credit for this as it was already in the works prior to the acquisition. The acquired company had already spent/allocated the money.

And while it could be argued otherwise, these acquisitions continue to consolidate IP and influence upwards to a smaller number of massive companies. Which long term will not benefit consumers

Edit: even if in process R&D is included, their 10-K shows only $802m attributed to “restructuring and acsquisition related costs” for 2021. And Im not seeing it anywhere else on the income statement/balance sheet/or statement of cash flows.

For Q3, as you’ll see in OP’s infographic, in-process R&D adds another $502m for a total of $3.2b in R&D. Way below their net income of $8.6b.

1

[deleted] t1_j03e15o wrote

I get what you’re saying, but when you look at the total cost a company spends on R&D, you have to include acquired R&D. A company spending money internally on R&D isn’t really different from a company spending money on a company for its R&D

1

kirlandwater t1_j03eiq8 wrote

I added this as an edit on my previous comment but I’ll paste it here as well

Even if in process R&D is included, their 10-K shows only $802m attributed to “restructuring and acsquisition related costs” for 2021. This was already included in my quoted figure netting $21.98b in net revenue for last year. And Im not seeing it anywhere else on the income statement/balance sheet/or statement of cash flows.

For Q3, as you’ll see in OP’s infographic, in-process R&D adds another $502m for a total of $3.2b in R&D. Way below their net income of $8.6b.

1